US Food and Drug Administration (USFDA) has concluded inspection at Indoco Remedies’ Goa Plant I (Oral Dosages Facility) with issuing 6 observations (483s) to the site. None of these observations are critical in nature. The company will respond to these observations within the stipulated time of 15 days.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.